Grisnilimab

Description: Grisnilimab (WT1) is a monoclonal antibody targeting CD7. CD7 plays a crucial role in T cell and T cell/B cell interactions, and the Wilms' tumour 1 (WT1) gene is overexpressed in leukaemia and various types of solid tumours (such as lung cancer and colorectal cancer). Target: Immunology/Inflammation related. References: Hertler AA, et al. An immunotoxin for the treatment of T-acute lymphoblastic leukemic meningitis: studies in rhesus monkeys. Cancer Immunol Immunother. 1989,28(1):59-66.